Biopharma News : Biopharma and Pharma news from all around the world :
- First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera’s Ability to Predict Overall Survival
- Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
- KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
- Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
- Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
- Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
- Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
- KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
- Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
- Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024
- BIOQUAL, Inc. Announces a Reduction in Workforce
- Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer
- bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
- Cellular Origins and 3P innovation Collaborate to Accelerate Industrialisation of CGT Manufacturing
- Closed Loop Medicine Appoints Luba Greenwood as Chair of the Board of Directors
- EORTC Extends Medidata Partnership to Help Power New Phase of Oncology Research
- A. Menarini Diagnostics and Nucleix Announce a Strategic Partnership for a Non-Invasive Bladder Cancer Test in Europe
- ArcanaBio Secures Funding from BioInnovation Institute to Revolutionize Healthcare with new Ultra-Rapid Liquid Biopsy Technology
- Epsilogen Completes £12.5 Million Series B Financing Expansion
- AHF: Equity for Africa in Pandemic Agreement Talks
- Poxel Reports Revenue for the Second Quarter and First Half 2024 and Provides Corporate Update
- BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024
- Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
- MedTech Innovator Asia Pacific Names APrevent Top 2024 Innovator in Grand Finals Competition
- Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
- Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
- Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients with Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
- Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
- Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
- Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
News about Biotech, Pharma, Biopharma, Medical Devices, Diagnostics, Digital Health
- CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
- Teilnahme an der Investora am 19. September 2024 und frühere Publikation des Halbjahresreports am 16. September
- Medacta Introduces a Simplified Approach for the M-ARS ACL Technique at the AGA Congress 2024, Mimicking the Native Ligament Footprint with an Optimized Surgical Flow
- Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange
- Change in the Chief Financial Officer at Biotest AG
- CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
- PharmaSGP Holding SE resolves on public share repurchase offer to buy back own shares for up to 594,405 shares
- PharmaSGP continues dynamic growth path in the first half of 2024
- Marinomed Biotech AG: First Carragelose products receive new Medical Device Regulation (MDR) certification
- Abivax presents first-half 2024 financial results
- Secarna Pharmaceuticals will present data at 6th Inflammasome Therapeutics Summit demonstrating the potential of ASOs to target the expression of NLRP3
- CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
- Preliminary IFRS result for the first half of 2024 EBIT increases significantly to 75.7 mn euros. Equity increases by EUR 74.5 mn to EUR 325.5 mn, which corresponds to EUR 76.02 per share.
- Promotion for SCHOTT Pharma: Listed on the MDAX for the first time
- MeVis Medical Solutions AG: Adjusting forecast for the current fiscal year
- Secarna establishes Scientific Advisory Board with leading oncology experts Prof. Dr. Eggermont and Prof. Dr. Zippelius
- Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
- Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
- EGS Beteiligungen AG exercises right to convert bond and increases its shareholding in Siegfried to 7.2% registered shares
- Operating Profit (EBIT) almost doubled: M1 Kliniken AG also grows significantly in the first half of 2024
- Evotec announces change in Management Board
- Xlife Sciences AG Completes Strategic Review Process by Q3 2024
- AEVIS VICTORIA SA (AEVS.SW) – Klinik Pyramide to be integrated into Privatklinik Bethanien in Zurich
- Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device
- Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights
- Viromed Medical AG: Successful start of trading on XETRA
- Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
- Siegfried opens new quality control lab in Minden
- Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
- Vita 34 continues positive trend in the first half of 2024 and once again significantly increases operating cash flow
- RYBREVANT®▼ (amivantamab) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
- Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024
- KFSHRC Revolutionizes Patient Care with Pioneering Experience Ambassadors Program
- Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
- Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
- Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
- Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
- RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
- Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
- Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
- Company Statement on FDA Advisory Committee Meeting
- Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.
- Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
- Fagron completes share buy-back program
- Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
- Virbac : Half-yearly financial report 2024
- Virbac : Public release of the Half-Year Financial Report at 30 June 2024.
- BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.
- NMDP℠ Organizes Nationwide Fundraisers to Propel Research, Aid Patients with Blood Cancer and Diseases
- NMDP℠ Organizes Nationwide Fundraisers to Propel Research, Aid Patients with Blood Cancer and Diseases
- RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
- RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
- Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CorMedix Inc. to Present at the Cantor Global Healthcare Conference
- CorMedix Inc. to Present at the Cantor Global Healthcare Conference
- Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
- FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
- FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
- Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
Sources for this page of Biopharma News : biopharma-reporter.com and worldpharmanews and pharmatimes.com and drugs.com and fiercepharma.com and scripintelligence.com and PR Newswire and Business Wire. Please visit all this very interesting websites for more info.
Biopharma News – Pharma News